AOD-9604 is a modified fragment of human growth hormone corresponding to amino acids 176-191 of the hGH sequence, engineered to isolate the fat-metabolizing region of the GH molecule without its broader growth-promoting…
🔬 Studied for: Fat-Metabolism Research
💊 Also studied for: Metabolic-Pathway Research
🧪 Not FDA-approved — sold strictly for laboratory research
📈 No standardized human dosage established in published literature
AOD-9604 is a modified fragment of human growth hormone corresponding to amino acids 176-191 of the hGH sequence, engineered to isolate the fat-metabolizing region of the GH molecule without its broader growth-promoting or insulin-desensitizing effects.
AOD-9604 is studied for its ability to stimulate lipolysis (fat breakdown) and inhibit lipogenesis (fat storage) in adipose tissue, reportedly without significantly activating the IGF-1 pathway associated with full-length growth hormone's anabolic and blood-sugar effects.
These are effects AOD-9604 has been studied for in available preclinical and early research — not claims about guaranteed outcomes.
AOD-9604 was originally developed by Australian biotech Metabolic Pharmaceuticals specifically to study GH's lipolytic fragment in isolation, and it remains the primary reference compound for that specific line of research.
Because it was designed to separate GH's fat-metabolism effects from its growth-promoting activity, AOD-9604 is studied as a tool for dissecting which regions of the GH molecule drive which physiological outcomes.
Doses used in the completed Phase IIb clinical trials are documented in the associated trial literature; this does not constitute a current recommendation for use of unregulated research material, for which no approved dosage exists.
Compound X does not provide dosing recommendations. AOD-9604 is sold for laboratory research use only and is not intended for human consumption.
AOD-9604 completed Phase IIb human obesity trials in Australia but did not demonstrate sufficient efficacy over placebo to proceed to further development, and it has not received FDA approval. Documented trial data found it to be generally well-tolerated at studied doses, though it is not approved for any indication.
No. AOD-9604 is not FDA-approved for any indication and is sold strictly as a research chemical, not a medication or dietary supplement.
Fat-Metabolism Research — AOD-9604 was originally developed by Australian biotech Metabolic Pharmaceuticals specifically to study GH's lipolytic fragment in isolation, and it remains the primary reference compound for that specific line of research.
In the US, UK, Canada and Australia, AOD-9604 is generally sold labeled "for research use only, not for human consumption." It is not approved as a dietary supplement or medication in any of these countries.
AOD-9604 clinical trial outcomes are indexed on PubMed under "AOD9604 obesity trial" and "AOD-9604 lipolytic fragment."
Compare current prices, purity testing claims and coupon codes across every vendor Compound X tracks.
New guides, vendor comparisons and compound breakdowns every week.